Login to Your Account



Neurosearch Pushes on with Huntington's Disease Drug

By Nuala Moran


Tuesday, January 4, 2011
LONDON – Neurosearch said it intends to press ahead and present the data on its Huntington's disease treatment Huntexil (pridopine) to regulators, following a meta-analysis of two studies that each individually failed to meet the primary endpoint.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription